ALSO NOTED: Medtronic launches first Asian JV; Pfizer ups dividend by 10%;

> Medtronic is buying a 15 percent stake in a Chinese medical-device maker for $221 million and launching its first Asian joint venture. Report

> Pfizer is boosting its quarterly dividend by 10% to 32 cents per share, just two months after reporting a 77 percent plunge in third-quarter profits. Report

> As part of its bid to raise cash, PDL BioPharma sold off its IV Busulfex cancer drug to Japan's Otsuka Pharmaceuticals for $200 million. Report

> China joined the list of countries that have suspended sales of aprotinin, a drug used to prevent blood loss during heart surgery; it's been linked with various adverse reactions. Some 20 manufacturers in China will be affected by the sales ban; it won't affect Bayer, whose aprotinin-containing Trasylol was suspended worldwide last month. Report

> Johnson & Johnson sold a device plant in New Bedford, MA, to Symmetry Medical, which makes orthopedic products, for $45 million; all 200 workers at the plant will keep their jobs. Report

> Pfizer's acquisition of Coley Pharmaceutical Group has cleared its antitrust review. Report

> The complex genetic machinery that manages our internal body clock is controlled by a single amino acid, which could prove to be one of the biggest new drug targets of the year. Report

> Several teams of scientists have been working away at creating new life forms from artificial DNA. Report

> Scientists at London's Imperial College have developed a patch made from embryonic stem cells to repair damaged hearts. Report

And Finally... We guess you could call this a business opportunity: Climate change is likely to make us all less healthy--and more in need of meds. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.